Related Experiment Videos
Lethal effects of reserpine plus physostigmine and neostigmine in mice
Abstract:
1. The interaction between the reversible cholinesterase inhibitors, physostigmine and neostigmine and reserpine was studied. 2. A combination of reserpine plus a cholinesterase inhibitor significantly increased lethality in adult male Swiss-Webster mice above that caused by either neostigmine, physostigmine, or reserpine alone. 3. Methscopolamine completely reversed this effect. 4. It would appear that the presence of the antiadrenergic agent, reserpine, increases the toxicity of cholinomimetic agents. 5. The above results may have clinical significance, since reserpine and cholinesterase inhibitors are used in the practice of medicine.
Insights
Combining reserpine with cholinesterase inhibitors like physostigmine and neostigmine significantly increases lethality in mice. This dangerous interaction, reversed by methscopolamine, highlights potential clinical risks.
Area of Science:
- Pharmacology
- Toxicology
- Neuroscience
Background:
- Reserpine is an antiadrenergic agent.
- Physostigmine and neostigmine are reversible cholinesterase inhibitors.
- Cholinesterase inhibitors and reserpine have clinical applications.
Purpose of the Study:
- To investigate the interaction between reserpine and cholinesterase inhibitors.
- To determine the effect of this combination on lethality.
- To explore potential clinical implications of this drug interaction.
Main Methods:
- Adult male Swiss-Webster mice were used.
- Mice were treated with reserpine alone, cholinesterase inhibitors alone, or combinations.
- Methscopolamine was administered to assess its effect on lethality.
Main Results:
- Combination of reserpine and cholinesterase inhibitors significantly increased lethality compared to individual agents.
- Methscopolamine completely reversed the increased lethality caused by the combination.
- Reserpine appears to enhance the toxicity of cholinomimetic agents.
Conclusions:
- The combination of reserpine and cholinesterase inhibitors presents a significant toxicity risk.
- The antiadrenergic properties of reserpine may contribute to increased cholinomimetic toxicity.
- These findings have potential clinical significance for patients using these medications concurrently.